To compare the results of medical treatment and antireflux surgery in patients with Barrett's esophagus (BE).
Summary Background Data
The treatment of choice in BE is still controversial. Some clinical studies suggest that surgery could be more effective than medical treatment in preventing BE from progressing to dysplasia and adenocarcinoma. However, data from prospective comparative studies are necessary to answer this question.
Methods
One hundred one patients were included in a randomized prospective study, 43 with medical treatment and 58 with antireflux surgery. All patients underwent clinical, endoscopic, and histologic assessment. Functional studies were performed in all the operated patients and in a subgroup of patients receiving medical treatment. The median follow-up was 5 years (range [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] in the medical treatment group and 6 years (range [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] in the surgical treatment group.
Results
Satisfactory clinical results (excellent to good) were achieved in 39 of the 43 patients (91%) undergoing medical treatment and in 53 of the 58 patients (91%) following antireflux surgery. The persistence of added inflammatory lesions was significantly higher in the medical treatment group. The metaplastic segment did not disappear in any case. Postoperative functional studies showed a significant decrease in the median percentage of total time with pH below 4, although 9 of the 58 patients (15%) showed pathologic rates of acid reflux. High-grade dysplasia appeared in 2 of the 43 patients (5%) in the medical treatment group and in 2 of the 58 patients (3%) in the surgical treatment group. In the latter, both patients presented with clinical and pH-metric recurrence. There was no case of malignancy after successful antireflux surgery.
Conclusions
These results show that there are no differences between the two types of treatment with respect to preventing BE from progressing to dysplasia and adenocarcinoma. However, successful antireflux surgery proved to be more efficient than medical treatment in this sense, perhaps because it completely controls acid and biliopancreatic reflux to the esophagus.
The aim of treatment for Barrett's esophagus (BE) is to bring symptoms under control, cure associated inflammatory lesions, and prevent the appearance of dysplasia and adenocarcinoma. The therapeutic options are medical treatment for life and antireflux surgery. As both are equally efficient in controlling symptoms and neither can cause the metaplastic segment to disappear, 1-4 some authors recommend medical treatment because it is less aggressive. [5] [6] [7] [8] However, there are clinical studies that seem to indicate that efficient surgical treatment manages to cure a higher rate of associated inflammatory lesions 2, 4 and is better than medical treatment in preventing BE from progressing to adenocarcinoma. 2, 9, 10 More recently, Spechler et al., 11 in a randomized controlled trial, have questioned the advantages of surgical treatment in preventing the development of adenocarcinoma. Due to the small number of long-term randomized prospective studies, the treatment of choice in BE is still controversial. The aim of this article is to present the results of a randomized prospective trial comparing medical and surgical treatment in patients with BE.
PATIENTS AND METHODS
From 1982 to 2000 a total of 146 patients diagnosed with BE were evaluated for inclusion in this prospective study. The condition was considered, until 1997, as the presence of columnar epithelium over 3 cm in length continuing into the cardia and confirmed histologically. From 1997 onward, patients with short Barrett's segment with intestinal metaplasia were also included. Excluded from the study were patients with stenosis of more than 1 cm in length and/or less than 1.2 cm in diameter (n ϭ 25) and patients who rejected randomization (n ϭ 8). The remaining 113 patients were randomly assigned to either medical or surgical treatment. Randomization was performed before assessment by computer-generated numbers, details of which were concealed in sequentially numbered, sealed, opaque envelopes. Two groups of patients were formed (medical treatment, n ϭ 51; antireflux surgery, n ϭ 62). During follow-up, another 12 patients (8 with medical treatment and 4 undergoing antireflux surgery) were also excluded because they rejected endoscopic surveillance. Therefore, the population study consisted of 101 patients: 43 receiving medical treatment and 58 undergoing antireflux surgery. The two groups were homogeneous with regard to epidemiologic, clinical, endoscopic, histologic, manometric, pH-metric, and Bilitec data ( Tables 1-3) .
Medical treatment for all patients (n ϭ 43) consisted of hygiene, diet, and postural measures as well as antisecretory drugs: H 2 antagonists (150 mg twice daily) initially and omeprazole (20 mg twice daily) from 1992 onward for all patients, and periodic dilatations in patients with stenosis.
Surgical treatment, always performed by the same surgical team, consisted in 56 cases of a short Nissen fundoplication (1.5-3 cm) over a 48 to 50 French bougie through a laparotomy. Short gastric vessels were divided if there was difficulty in mobilizing the gastric fundus, which occurred in 36 cases (39%). To prevent the fundoplication from sliding towards the thorax, the wrap was sutured to the diaphragm, and in all cases we reduced the size of the hiatus by joining the right and left limbs of the crura posterior to the esophagus with one to three sutures of nonresorbable material. In the remaining two patients in whom esophageal shortening prevented us from achieving a sufficient length of intra-abdominal esophagus, a Collis-Nissen procedure was performed. Dilatations were carried out before and after operation in patients with stenosis.
All patients underwent annual clinical, endoscopic, and histologic assessment. To check the efficiency of the antireflux procedure, pH-metric and manometric studies were carried out in all the operated patients 1 year postoperatively and then every 5 years, or when the symptoms of gastroesophageal reflux reappeared. Twenty-four-hour pH monitoring was also carried out in 12 patients while on medical treatment. The study with the Bilitec 2000 was performed in 12 patients who were under medical treatment for 1 year and in 12 patients 1 year postoperatively.
Clinical assessment was done annually by direct interview, following a questionnaire directed towards discovering the presence of reflux symptoms and undesirable side effects of the Nissen fundoplication (e.g., dysphagia, postprandial fullness, inability to belch or vomit). The survey in all cases was carried out separately by the same two independent investigators, experienced in assessment of gastroesophageal reflux disease, who later compared results. The patients on medical treatment were classified as follows: excellent (asymptomatic), good (minimal symptoms requiring no additional therapy), fair (improved but with heartburn requiring additional therapy and/or dilatations in case of stenosis; and/or when regurgitation persisted), and poor (unimproved or worse). The clinical results in the operated patients were classified as excellent (asymptomatic), good (minimal symptoms requiring no therapy), fair (improved but with symptoms requiring intermittent therapy with, for instance, dilatation or antisecretory drugs), and poor (unimproved or worse).
The endoscopic study was performed in all patients by the same endoscopist. The presence of added inflammatory lesions was assessed. The length of segment of BE was measured taking the incisors, squamocolumnar junction, and cardia as reference points. Multiple biopsies were taken systematically during endoscopy, as described previously. 2 Dysplasia was graded according to Rydell et al. 12 Functional studies were performed according to the methodology previously described. 2, 13, 14 The mean, standard deviation, median, and range were calculated for all data. The comparisons between the two groups were performed with the Student t test for quantitative variables and with the chi-square Pearson test for qualitative variables. The comparisons between data before and after each type of treatment were performed with the Student t test for quantitative variables and with the McNemar test for qualitative variables.
The study was approved by the Ethics Committee of the Murcia University Hospital Virgen de la Arrixaca. Informed consent was obtained from all study participants.
RESULTS
After a median follow-up of 5 years (range 1-18), the clinical results in the medical treatment group were satis-factory (excellent to good) in 39 of the 43 patients (91%) and fair in 4 of the 43 (9%). Three patients (5%) required a median of 3 (range, 2-7) dilatations.
In the surgical treatment group there were no deaths related to the operation. As for complications, one splenectomy was necessary. Thirteen patients (22%) showed inability to belch or vomit and 17 (29%) had mild and transitory postoperative dysphagia that disappeared spontaneously. The median follow-up in this group was 6 years (range 1-18), and the results were satisfactory in 53 of the 58 patients (91%), fair in 4 (7%), and poor in 1 (2%), without statistically significant differences with respect to the medical treatment group. Postoperative dilatations due to the persistence of stenosis were necessary in one patient who required three dilatations (not significantly different from medical treatment).
The endoscopic changes in both groups are shown in Table 4 . Complete disappearance of intestinal metaplasia was not demonstrated in any case. Table 5 shows the results of the postoperative functional studies. There was a significant decrease in the median percentage of total time with pH below 4, although 9 of the 58 patients (15%) showed pathologic rates of acid reflux Treatment Of Barrett's Esophagus (median 19.5%, range 5-46%). These nine patients included the five with clinical recurrence. In the subgroup of 12 operated patients in whom pH and Bilitec studies were performed simultaneously, antireflux surgery totally controlled both acid and biliopancreatic reflux in all but one patient, in whom surgery failed (Fig. 1) . In contrast, in the subgroup of 12 asymptomatic patients under medical treatment, we found a significant decrease in the acid rate from 16% (range 6 -43%) to 0.9% (range 0 -9%) (P Ͻ .05), although in 3 of 12 cases (25%) pathologic rates of acid reflux were found (Fig. 2) . The Bilitec study in this subgroup (n ϭ 12) also showed a decrease in the biliopancreatic reflux rate from 31% (range 6 -66%) to 15.4% (range 2-32%), although this decrease was not statistically significant and 9 of the 12 patients (75%) had pathologic rates of duodeno gastroesophageal reflux (Fig. 2) . As far as progression to dysplasia or adenocarcinoma is concerned, there were no statistically significant differences between the groups. Table 6 shows the histologic changes in the medical treatment group (n ϭ 43), in the surgical treatment group (n ϭ 58), and in the successful surgical treatment group (the 9 patients who showed pH-metric recurrence of reflux being excluded) (n ϭ 49). In the medical treatment group, dysplasia de novo appeared in 8 of the 40 patients (20%); 2 of these 8 patients developed highgrade dysplasia. In three of these eight patients medical treatment consisted of H 2 -blockers, another three patients were treated initially with H 2 -blockers and from 1992 onward with omeprazole, and the remaining two were treated with omeprazole alone. In the surgical treatment group, dysplasia de novo appeared in 3 of the 53 patients (6%); 2 of the 3 developed high-grade dysplasia. These two patients showed clinical and pH-metric recurrence of gastroesophageal reflux 1 year postoperatively; the percentage of total time with pH below 4 was 12% and 37%. Medical treatment was given to these two patients and high-grade dysplasia appeared after a follow-up of 4 and 6 years postoperatively. In the four patients with high-grade dysplasia, an esophageal resection was performed and an adenocarcinoma was found in all cases. Data concerning these four patients are summarized in Table 7 . Finally, dysplasia de novo appeared in only 1 of 44 patients (2%) in the successful surgical treat- ment group, with no case of high-grade dysplasia. The incidence of dysplasia de novo in this group showed a statistically significant difference with respect to that of the medical treatment group (P Ͻ .05). The rate of malignancy was 1 in 129 patient-years (0.8% per year) for the medical treatment group and 1 in 203 patient-years (0.5% per year) for the surgical treatment group, with no significant differences. When surgery was successful, there was no case of malignancy.
DISCUSSION
The premalignant potential of BE might vary depending on the treatment used. As surgery manages to restore the competence of the lower esophageal sphincter, it not only suppresses acid reflux but also the reflux of the duodenal contents, whereas medical treatment with antisecretory drugs does not manage in all cases to normalize the reflux of Treatment Of Barrett's Esophagus duodenal contents to the esophagus 15, 16 or in some cases acid reflux, 3, [17] [18] [19] even if the patient is asymptomatic. In some cases the persistent irritating action of the acid and the bile might continue to harm the metaplastic mucosa and favor the progression of lesions. Only comparative studies between the two types of treatment will enable us to determine which is more efficient in preventing progression to dysplasia or adenocarcinoma. However, it will not be easy because although there is a risk of malignancy, it is low, and we would need studies with a large number of patients and long-term follow-ups to show significant differences. In 1991, McCallum et al., 10 in a nonrandomized prospective study, suggested that surgery prevents the development of dysplasia and adenocarcinoma better than medical treatment. Katz et al. 9 reached identical conclusions in 1998 in a retrospective study of 102 patients. In 1996, we 2 published a randomized prospective study comparing medical treatment (n ϭ 27) and antireflux surgery (n ϭ 32) with a mean follow-up of 4.7 years and 5 years, respectively. This study suggested that successful Nissen fundoplication seems to be more efficient than medical treatment in preventing BE from progressing to adenocarcinoma. More recently, Spechler et al., 11 in a randomized controlled trial comparing the long-term outcome of medical and surgical therapies for gastroesophageal reflux disease, questioned the advantages of surgical treatment in preventing the development of adenocarcinoma, although in view of the low incidence of this neoplasm, the same authors considered that their study did not have sufficient statistical power to detect significant differences.
The results of the present study, which now includes 101 patients with a longer follow-up, confirm those we have published previously. 2 From a clinical point of view, we found no differences between the two types of treatment. The percentage of satisfactory postsurgery results in our series is higher than that reported by other authors, 20 -22 possibly related to the fact that patients with severe esophageal stenosis (n ϭ 25) were excluded from randomization.
The endoscopic data demonstrate the greater efficiency of surgery for curing associated inflammatory lesions, although we did not observe the complete disappearance of intestinal metaplasia in any of our patients.
The postoperative functional studies showed that Nissen fundoplication improves the mechanical conditions of the lower esophageal sphincter and reduces the rate of pathologic acid reflux. However, it also revealed that 9 of 58 patients (15%) had pathologic rates of acid reflux, with only 5 (9%) presenting with clinical recurrence. As for the Bilitec study (n ϭ 12), antireflux surgery totally controlled the biliopancreatic reflux in all but one case in which surgery failed. Unfortunately, we have no functional studies in all the patients under medical treatment, but in a subgroup of 12 patients, omeprazole (40 mg daily) reduced but did not control the biliopancreatic reflux or the acid reflux in all the cases, despite the patients being asymptomatic.
As far as progression to dysplasia or adenocarcinoma is concerned, there were no statistically significant differences between both types of treatment. However, if we exclude from the study patients in whom surgery failed (n ϭ 9) and compare only patients with successful surgery (n ϭ 49) with all the patients under medical treatment (n ϭ 43), our results also show that total control of acid and biliopancreatic reflux to the esophagus obtained by a successful Nissen fundoplication significantly reduces the risk of BE progressing to dysplasia and adenocarcinoma. It might not be appropriate to compare the results of the subgroup of patients who have undergone successful surgery with those of the entire medical group because it introduces bias, since a substantial proportion of patients under medical therapy continued to have pathologic levels of acid and biliary reflux. In this sense, it would be more reasonable to compare two successful therapy groups, but then there exists the question of how to define medical therapy as "successful": is it sufficient to control acid reflux, or is it necessary to control biliary reflux too? Our results showed that 40 mg omeprazole failed to normalize acid reflux in 3 of the 12 patients (25%) and biliary reflux in 9 of the 12 patients (75%). Maybe the dose of omeprazole necessary to control both types of reflux is in some cases too high to be recommended as long-life treatment. Some authors [5] [6] [7] [8] 11, 23, 24 advocate medical treatment in patients with BE since there is no conclusive evidence that surgery prevents malignancy, and the risk of malignancy is low and similar to the risk of mortality related to surgery. Furthermore, surgery has morbidity. However, if we exclude from surgery patients with a high surgical risk, we can reduce the mortality to near zero. In addition, surgery is less expensive than medical treatment for life, prevents the possible side effects of the latter, and can be performed in many cases using a laparoscopic approach. [25] [26] [27] [28] In summary, our results show that the risk of malignancy is similar with both types of treatment. Therefore, we cannot recommend surgery as the treatment of choice in all patients with BE. However, these data also demonstrate that in patients in which surgery was successful (85% in our series), the risk of progression to dysplasia and adenocarcinoma is significantly lower than in patients under medical treatment. Consequently, we question the systematic medical approach for these patients. Although randomized prospective studies with more patients and longer follow-up will be necessary, our data support that surgery could be the treatment of choice in many patients with BE, especially if they are young and/or have low surgical risk. The possibility that surgery might fail (15% in our series) or have side effects should be balanced against the fact that successful surgery controls the low but evident risk of malignancy better than medical treatment. Perhaps the opinion of correctly informed patients could be taken into account.
